Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Localized Injection of STP705 in Adult Patients With Basal Cell Carcinoma

Next Previous
X
Search
Trial Profile

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Localized Injection of STP705 in Adult Patients With Basal Cell Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 705 (Primary) ; STP 705 (Primary)
  • Indications Basal cell cancer; Carcinoma
  • Focus Therapeutic Use
  • Sponsors Sirnaomics

    • Most Recent Events

    • 28 Mar 2024 According to Sirnaomics media release, the Company will hold the End-of-Phase II meeting with the U.S. FDA to obtain guidance on the future path forward for the late-stage development of STP705 for the treatment of BCC
    • 15 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2024 Number of treatment arms increased from 3 to 7 by the addition of separate arms for the doses 120, 180, 240 and 320 micrograms.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top